Novartis’ Gilenya proves superiority over glatiramer acetate in relapsing remitting MS

This article was originally published here

The results demonstrated Gilenya 0.5mg’s superior efficacy over glatiramer acetate 20mg in reducing the annualized relapse rate (ARR), a key measure of disease activity, with a 40.7% relative

The post Novartis’ Gilenya proves superiority over glatiramer acetate in relapsing remitting MS appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply